ArticleCell reports. Medicine2025

TIMEPOINT, a phase 1 study combining MTL-CEBPA with pembrolizumab, supports the immunomodulatory effect of MTL-CEBPA in solid tumors.

Ruth Plummer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.